Niall Martin
CEO
Artios
The startup develops targeted cancer therapies that exploit DNA damage response pathways to induce synthetic lethality in cancer cells. By focusing on specific mutations, their treatments aim to enhance the selective destruction of malignant cells while minimizing harm to healthy tissue.
- Biotechnology
Updated 21 months ago
Funding
Raised to date
$270.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many cancers develop resistance to existing treatments by exploiting DNA Damage Response (DDR) pathways, which repair damaged DNA and allow cancer cells to survive and proliferate. Selectively targeting these DDR pathways in cancer cells, while sparing healthy cells, remains a significant challenge.
Solution
Artios Pharma is developing targeted cancer therapies that exploit DNA Damage Response (DDR) pathways to induce synthetic lethality in cancer cells. Their approach focuses on inhibiting specific DDR targets, such as ATR and Polθ, to selectively disrupt DNA repair mechanisms in malignant cells. By targeting these pathways, Artios aims to enhance the destruction of cancer cells while minimizing harm to healthy tissue. Their DcoDeR platform enables the identification of novel DDR targets, expanding the possibilities for therapeutic intervention.
Target Audience
The primary target audience includes patients with cancers that exhibit dysregulation of DNA Damage Response pathways, as well as pharmaceutical companies seeking to expand their oncology portfolios through strategic partnerships and innovative drug development.
Features
- ART0380: Orally dosed ataxia telangiectasia and Rad3-related protein (ATR) inhibitor with the potential to induce DNA damage in sensitive cancer tissue while preserving DNA integrity in healthy tissue.
- ART6043: Polθ inhibitor designed to specifically target tumor cells while sparing normal tissue from toxicity, potentially effective across multiple tumor types, including PARP inhibitor-resistant cancers.
- DcoDeR platform: A drug discovery platform for identifying novel DDR targets in disease settings with unmet medical needs.
- Research collaborations: Partnerships with Novartis and Merck KGaA to identify DDR targets and agents for use with radioligand therapies and nuclease inhibitors, respectively.
- Immuno-oncology combinations: Exploring combinations of DDR-targeted therapies with immunotherapies to enhance the immune system's ability to target and kill cancer cells.